OpRegen, developed by Israel’s CellCure NeuroSciences is designed to treat patients with the severe stage of the dry form of age-related macular degeneration (dry-AMD).  Dry-AMD is the leading cause of visual impairment in an aging population.  No approved therapy currently exists.

http://www.cellcureneurosciences.com/biotimes-subsidiary-cell-cure-neurosciences-ltd-files-an-ind-with-the-fda-for-opregen-designed-to-treat-patients-with-dry-amd/